IA2030 Scorecard
—Global
Type to select a Country
If target is reached, 50 million total future deaths will be averted during 2021-2030 and an annual average of 5 million deaths will be averted each year.
Pathogen | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|
Total | 4,196,175 | 4,139,432 | 3,972,892 | 4,103,301 |
Hib | 202,806 | 195,828 | 192,552 | 200,798 |
JE | 11,325 | 9,727 | 8,929 | 10,164 |
Measles | 1,656,417 | 1,627,715 | 1,588,183 | 1,621,598 |
MenA | 5,303 | 5,420 | 5,855 | 4,606 |
Streptococcus pneumoniae | 140,117 | 140,364 | 138,080 | 157,694 |
Pertussis | 480,592 | 457,090 | 442,486 | 467,741 |
Rotavirus | 32,320 | 35,967 | 35,251 | 35,866 |
Rubella | 45,557 | 43,263 | 41,711 | 42,540 |
TB (BCG) | 119,941 | 114,828 | 111,045 | 117,444 |
Tetanus | 43,171 | 41,011 | 39,556 | 41,876 |
Yellow fever | 125,334 | 124,390 | 123,277 | 123,764 |
Diphtheria | 15,154 | 14,286 | 13,767 | 14,774 |
HPV | Not measured | 61,299 | 57,237 | 80,613 |
Hepatitis B | 1,318,139 | 1,268,243 | 1,174,963 | 1,183,823 |
Step 1) Estimated deaths and deaths averted, collected from multiple data sources, are converted into a single measure of country-, age-, and vaccine-specific relative risk of death conditional upon vaccine coverage levels.
Step 2) Relative-risk model is used to predict deaths averted in all locations and diseases.
Step 3) Additional calibration converts the estimates into deaths averted by year of vaccination, which allows for capturing the lifetime effect of vaccination aggregated for the year the vaccines are delivered.
A counterfactual of “no vaccination”, as opposed to partial vaccination, is used to calculate the estimates, and vaccine coverage estimates capture only vaccines delivered through the routine immunization system (the impact on vaccine coverage from supplementary immunization activities (SIAs) is not captured).
Limitations on population estimates used to calculate model estimates can be found on the WPP website, and include: